Page 43 | Certara

Poster

A Mechanistic PK/PD Model for First-in-Human Dosing of a Tetraspecific Antibody (MDX2001) for the Treatment of Advanced Solid Tumors

MDX2001 is a tetraspecific T cell engager that binds CD3 and CD28 on T cells…

CertaraNovember 22, 2024

Poster

Model-Informed Drug Development Framework for the Development and Dose Optimization of Targeted Radiation Therapies

CertaraNovember 22, 2024

Poster

Augmented Definitive Screening Design Provides Efficient Phase 1 Selection of CAR T-cell and Lymphodepletion Regimen

CertaraNovember 22, 2024

Poster

Oncology MIDD Simulator, A User-Friendly Application for Overall Survival Forecasting in Early Oncology Trials

CertaraNovember 22, 2024

Poster

Quantitative Systems Pharmacology model for combined targeting of BAFF and CD40 pathways in systemic lupus erythematosus

CertaraNovember 22, 2024

Poster

Population pharmacokinetic modeling of niraparib to assess different absorption models

CertaraNovember 22, 2024

Blog

A Medical Writer’s Guide to Collaborative Authoring

Once upon a time, regulatory writing for drug development programs followed a scheduled routine and…

CertaraNovember 22, 2024

Publication

Real-world application of physiologically based pharmacokinetic models in drug discovery

The utility of physiologically based pharmacokinetic (PBPK) models in support of drug development has been…

CertaraNovember 22, 2024

Blog

Top Three Insights from Certainty Europe

The first European Certainty Conference for the Certara Client Community in Mainz Germany was full…

CertaraNovember 21, 2024

Video

Expert Insights into Early Drug Development

CertaraNovember 21, 2024

© 2025 Certara. All Rights Reserved. | Legal | Privacy policy